AKT1 and breast carcinoma: We treated cells with the p110α inhibitor BYL-719, AKT inhibitor LY294002, or AKT agonist SC79 to determine whether TSP50 promotes breast cancer CSC-like traits, EMT and metastasis through the PI3K/AKT signaling pathway.